Oct 22nd 2012 - Edison Investment Research today published a report on Lombard Medical Technologies (LMT.L, LSE:LMT, LON:LMT) entitled "Runway Cleared For Take Off?". In summary, the report says:
FDA feedback in the approval process for the Aorfix endograft included a set of questions that Lombard expects to respond to shortly. It continues to anticipate US approval for the device in Q412. However, if the decision shifts into Q113, Lombard would need to arrange a new round of financing to replace a £13.6m equity tranche contingent on 2012 approval. H112 trading was mixed although key markets performed well with 23% increase in procedures using Aorfix. Our valuation, assuming 2012 approval and funding is £97.7m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »